BMYB34 Stock Overview
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 4/6 |
Bristol-Myers Squibb Company Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$231.50 |
52 Week High | US$342.38 |
52 Week Low | US$229.50 |
Beta | 0.39 |
1 Month Change | -11.39% |
3 Month Change | -4.93% |
1 Year Change | -32.37% |
3 Year Change | -31.47% |
5 Year Change | 21.24% |
Change since IPO | 251.40% |
Recent News & Updates
Recent updates
Shareholder Returns
BMYB34 | BR Pharmaceuticals | BR Market | |
---|---|---|---|
7D | -8.5% | -2.5% | -0.2% |
1Y | -32.4% | -20.6% | 13.7% |
Return vs Industry: BMYB34 underperformed the BR Pharmaceuticals industry which returned -15.4% over the past year.
Return vs Market: BMYB34 underperformed the BR Market which returned 13.9% over the past year.
Price Volatility
BMYB34 volatility | |
---|---|
BMYB34 Average Weekly Movement | 4.9% |
Pharmaceuticals Industry Average Movement | 6.0% |
Market Average Movement | 4.7% |
10% most volatile stocks in BR Market | 8.8% |
10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: BMYB34 has not had significant price volatility in the past 3 months.
Volatility Over Time: BMYB34's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1887 | 34,100 | Chris Boerner | www.bms.com |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
Bristol-Myers Squibb Company Fundamentals Summary
BMYB34 fundamental statistics | |
---|---|
Market cap | R$467.82b |
Earnings (TTM) | -R$31.75b |
Revenue (TTM) | R$235.13b |
2.0x
P/S Ratio-14.7x
P/E RatioIs BMYB34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BMYB34 income statement (TTM) | |
---|---|
Revenue | US$45.53b |
Cost of Revenue | US$10.88b |
Gross Profit | US$34.65b |
Other Expenses | US$40.80b |
Earnings | -US$6.15b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 26, 2024
Earnings per share (EPS) | -3.03 |
Gross Margin | 76.10% |
Net Profit Margin | -13.50% |
Debt/Equity Ratio | 135.1% |
How did BMYB34 perform over the long term?
See historical performance and comparison